What happened with FATE today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Fate Therapeutics is developing cell therapies for cancer and autoimmune diseases. It engineers human stem cells that can become different cell types, then uses selected cell lines to produce T cells and natural killer cells for treatment. The platform is designed to make standardized batches that can be frozen and supplied off the shelf. Its candidates remain in research or early clinical development; none is approved, and it has no therapeutic-product sales.
Its current revenue comes from its collaboration with Ono, which pays Fate to research and develop cell-therapy candidates for solid tumors. These include FT825 / ONO-8250, a CAR T-cell candidate targeting tumors that express HER2. Fate and Ono are jointly developing it and have agreed to co-commercialize it in the United States and Europe. The collaboration also offers potential milestone payments and royalties on future sales in territories where Ono has exclusive commercialization rights.
Fate therefore depends on Ono for collaboration revenue, while product sales require successful clinical development and regulatory approval. It also needs additional capital to fund development, manufacturing and eventual commercialization.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Fate Therapeutics’ prospects hinge on clinical success for its off-the-shelf engineered cell therapies and on Ono Pharmaceutical, its sole current source of collaboration revenue and partner for HER2-targeting FT825 and another solid-tumor candidate.
Century Therapeutics competes with Fate Therapeutics by developing ready-made T-cell and natural-killer-cell therapies from clonally engineered induced pluripotent stem cells (iPSCs) for cancer and immune disorders. Watch whether Century’s cells can resist patients’ immune rejection and persist—the same hurdle Fate’s engineering aims to overcome.
Nkarta offers a competing route to Fate Therapeutics’ ready-made natural-killer-cell treatments: it engineers healthy donors’ cells rather than deriving them from iPSCs, then freezes them for use. Its NKX019 studies in autoimmune diseases are a concrete test of this donor-cell approach; Nkarta had no product sales through December 31, 2025.
Allogene Therapeutics competes with Fate Therapeutics in ready-made cancer treatments that engineer T cells to attack tumors, using donor cells rather than Fate’s iPSC-derived cells. Its cancer programs provide a comparison for that approach, while all its revenue through December 31, 2025 came from licensing rights to Overland Therapeutics.
Artiva Biotherapeutics competes with Fate Therapeutics in ready-made natural-killer-cell treatments, with its HER2-targeting AB-201 overlapping directly with Fate’s HER2-directed FT825 cancer program. Watch AB-201’s collaborator-funded development; Artiva’s rights exclude Asia, Australia and New Zealand.
Adicet Bio competes with Fate Therapeutics’ ready-made cancer cell therapies by engineering donors’ gamma delta T cells, rather than using iPSC-derived cells. Its ADI-212 program for metastatic castration-resistant prostate cancer is the cancer development to watch after it discontinued ADI-270.
Caribou Biosciences competes with Fate Therapeutics by making multiple edits to T cells for use across patients, offering an alternative to cancer treatments made separately for each patient. Watch its phase 1 trials of vispa-cel in relapsed or refractory B-cell non-Hodgkin lymphoma and CB-011 in relapsed or refractory multiple myeloma.
Cellectis competes with Fate Therapeutics in gene-edited T-cell treatments that can be frozen and supplied ready-made for blood cancers and solid tumors. Its UCARTFAP and UCARTMUC1 solid-tumor candidates remain preclinical, making their progress a useful comparison for Fate’s solid-tumor ambitions.
Sana Biotechnology competes with Fate Therapeutics on a central challenge for ready-made cell treatments: keeping the cells active while limiting rejection by the patient’s immune system. Sana develops immune-evasive cells for use across patients, while Fate engineers iPSC-derived cells toward the same goal.
Cabaletta Bio competes with Fate Therapeutics for treating B-cell-mediated autoimmune diseases, but makes engineered T-cell treatments from each patient’s own cells rather than using Fate’s ready-made approach.
Kyverna Therapeutics competes with Fate Therapeutics in autoimmune disease treatments that engineer T cells to reset disease-causing B-cell populations; Fate pursues a ready-made cell approach.
CRISPR Therapeutics competes with Fate Therapeutics by gene-editing T cells for ready-made immune-cell treatments used across patients. Its CAR T-cell candidates for cancer and autoimmune disease—not its approved blood-disorder treatment CASGEVY—are the programs most directly relevant to Fate.
Cartesian Therapeutics competes with Fate Therapeutics in autoimmune disease treatment, modifying each patient’s own T cells with mRNA rather than supplying Fate’s ready-made CAR T-cell approach.
Senti Biosciences competes with Fate Therapeutics in engineered natural-killer-cell treatments for cancer, using gene circuits in CAR NK cells rather than Fate’s multiple-engineering approach to ready-made NK cells.
Legend Biotech already competes with Fate Therapeutics’ blood-cancer treatments through commercial CARVYKTI, while also developing CAR T-cell and CAR NK-cell therapies for use across patients. Watch those allogeneic programs’ phase 1 trials in China for multiple myeloma and non-Hodgkin lymphoma; Legend also shares CARVYKTI’s commercial economics with Janssen.
Lyell Immunopharma competes with Fate Therapeutics in engineered CAR T-cell treatments for blood cancers and solid tumors, with both trying to keep cells active longer in difficult tumor environments. Watch LYL273’s solid-tumor development for evidence that Lyell’s technologies can overcome cell exhaustion and tumor immune suppression.
Cullinan Therapeutics competes with Fate Therapeutics’ autoimmune cell therapies by developing a ready-made drug that brings T cells to CD19-bearing, disease-causing B cells to eliminate them—a T-cell engager that avoids manufacturing therapeutic cells.
Adicet Bio, Inc. earningsACET
Adicet Bio’s report will show whether its prostate-cancer program ADI-212 is advancing, offering a comparison for Fate Therapeutics’ ready-made cancer cell therapies.
Track clinical progress for ADI-212, particularly whether the prostate-cancer study advances after ADI-270 was discontinued. Progress would show another engineered-cell approach still competing for cancer patients and development resources; a stall or setback would mean less near-term pressure on Fate’s cancer programs, not evidence of how Fate’s own candidates are performing.
Cullinan Therapeutics, Inc. earningsCGEM
Cullinan Therapeutics’ report will show progress on its CD19 T-cell engager, a drug that targets the disease-causing B cells Fate Therapeutics’ autoimmune cell therapies also seek to eliminate without making therapeutic cells.
Watch whether Cullinan advances its CD19 T-cell engager. Progress would show a drug that avoids making therapeutic cells is also pursuing the removal of disease-causing B cells, giving Fate’s autoimmune programs an alternative to compete against; a stall or setback would leave that route less advanced, not prove Fate’s cells work or are safer.
Nkarta, Inc. earningsNKTX
Nkarta’s report will show how its donor-derived NKX019 autoimmune studies are progressing, a comparison for Fate Therapeutics’ ready-made iPSC-derived cell approach.
Watch whether NKX019’s autoimmune studies advance. Progress would show a donor-derived, ready-made NK-cell treatment pursuing the same medical need as Fate’s approach; delays or setbacks would leave that competing route further behind, but would not show that Fate’s cells work or that its manufacturing and supply challenges are solved.
Lyell Immunopharma, Inc. earningsLYEL
Lyell Immunopharma’s report will show progress on solid-tumor candidate LYL273, a comparison for Fate Therapeutics’ effort to keep engineered cells active in tumors.
Track LYL273’s solid-tumor development and whether Lyell’s technologies support continued cell activity. Progress would show a competitor advancing against cell exhaustion and immune suppression in tumors; a stall or setback would weaken that comparison, but would not establish how Fate Therapeutics’ candidates perform.
Artiva Biotherapeutics, Inc. earningsARTV
Artiva Biotherapeutics’ report will show how its collaborator-funded HER2-targeting AB-201 is progressing, a direct comparison for Fate Therapeutics’ HER2-directed FT825.
Look for AB-201 development progress alongside continued collaborator support. Progress with support intact means Fate’s FT825 faces a direct HER2-targeted, ready-made NK-cell competitor that is advancing; a stall or weaker support means less direct competition in that approach, but does not establish that FT825 works or can be commercialized.
Fate Therapeutics, Inc. earningsThis company
Fate Therapeutics earns collaboration revenue from research and development, and this report will show whether Ono’s payments continue to cover part of its research costs.
Read collaboration revenue alongside research and development spending. Higher collaboration revenue with controlled spending would show Ono’s funding is still carrying part of the research cost. If revenue falls without a matching drop in spending, Fate bears more of the cost, putting greater pressure on cash and future financing.
Century Therapeutics, Inc. earningsIPSC
Century Therapeutics’ report will show whether its iPSC-derived T and NK cells can resist immune rejection and persist, the same hurdle facing Fate Therapeutics’ ready-made cells.
Look for evidence that Century’s T-cell and NK-cell programs can resist immune rejection and persist. Progress would show a close iPSC-derived, ready-made cell competitor addressing a key hurdle; a lack of progress or setbacks would leave that shared challenge unresolved, not answer how Fate’s cells perform.
Senti Biosciences Holdings, Inc. earningsSNTI
Senti Biosciences’ report will show progress on its gene-circuit-engineered NK-cell cancer programs, a comparison for Fate Therapeutics’ ready-made NK-cell approach.
Watch whether Senti advances its gene-circuit NK-cell cancer programs. Progress would show another engineered, ready-made NK-cell design moving toward clinical use; delays or setbacks would leave that design less advanced, but would not show that Fate Therapeutics’ approach is more effective.
